Csenge Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Csenge Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Buy	5,037 +2,354	+88%	+$516K	0.05%	280
2026 Q1	$507K	Buy	+2,683	New	+$469K	0.02%	429
2020 Q1	–	Sell	-1,378	Closed	-$206K	–	321
2019 Q4	$206K	Buy	+1,378	New	+$188K	0.05%	276
2019 Q3	–	Sell	-1,506	Closed	-$214K	–	279
2019 Q2	$214K	Sell	1,506 -91	-6%	-$12.2K	0.07%	174
2019 Q1	$228K	Buy	+1,597	New	+$208K	0.08%	179

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Csenge Advisory Group's JAZZ Position: Q2 2026 in Review

Csenge Advisory Group increased its Jazz Pharmaceuticals (JAZZ) stake by 88% in Q2 2026, buying an estimated $516K and bringing the position to 5,037 shares worth $1.21M. The position accounts for 0.05% of the portfolio, ranked #280.

Csenge Advisory Group first reported a position in JAZZ in Q1 2019 and has held it in 5 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Csenge Advisory Group held 5,037 shares of Jazz Pharmaceuticals worth $1.21M as of Q2 2026.
Csenge Advisory Group bought 2,354 Jazz Pharmaceuticals shares in Q2 2026, an estimated $516K.
Jazz Pharmaceuticals made up 0.05% of Csenge Advisory Group's portfolio in Q2 2026, its #280 holding.
Csenge Advisory Group first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 5 quarters since.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.